Presentation provides detail on how Agalimmune’s lead small molecule immunotherapeutic, AGI-134, displays potent anti-tumour activity as a stand-alone therapy and combines synergistically with an anti-PD1 checkpoint inhibitor
London, UK, May 25, 2016 – Agalimmune Ltd, an innovative anti-cancer immunotherapy biopharmaceutical company developing treatments for patients with solid tumours, announces today that Dr Sascha Kristian, Research Director, Agalimmune, will deliver a presentation on Agalimmune’s lead clinical candidate, AGI-134 and its potent anti-tumour activity. The presentation will be delivered at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting, June 3-7 2016 in Chicago, Illinois, US.
AGI-134 is in development for the treatment of solid tumours and is in preparation for a phase I/II clinical study. AGI-134 is a fully synthetic, alpha-Gal glycolipid-like small molecule with a unique mechanism of action that drives a patient-specific anti-tumour response in situ.
The presentation (abstract ID 3083) is entitled “AGI-134, a fully synthetic a-Gal-based cancer immunotherapy that shows synergy with an anti-PD-1 antibody and favourable pre-clinical pharmacokinetic and toxicity profiles”. It will provide the latest results demonstrating that AGI-134 displays potent anti-tumour activity. AGI-134 engages the cellular and humoral immune systems in situ against autologous tumour neoantigens, to attack the patient’s own tumour cells all around the body.
The presentation includes data generated in an in-vivo model of melanoma. These data show that AGI-134 monotherapy induces an immune response that prevents the growth of distant untreated lesions. Importantly they also show that AGI-134 combines synergistically with an anti-PD1 checkpoint inhibitor. In addition, the results show that AGI-134 has an ideal profile as a clinical candidate with very good tolerability and favourable pharmacokinetics.
The presentation will be made in the poster session Developmental Therapeutics—Immunotherapy on Sunday 5 June between 8.00am and 11.30am.
“This presentation highlights the strong potential of AGI-134 as a novel immunotherapy for solid tumours. The unique mechanism of action of AGI-134 addresses directly two key issues in cancer therapy. The first is inter and intra-patient tumour neoantigen heterogeneity. This has recently been highlighted in a key paper in Science [1]. The second is the non-inflammatory, or cold, tumour microenvironment, that limits responsiveness to existing immunotherapies,” said Dr. Sascha Kristian, Research Director at Agalimmune. “Current immunotherapies alone lead to durable responses in less than half of patients and are associated with significant side effects. There is a huge need for therapies like AGI-134 that can increase the frequency and duration of responses. Furthermore, as a small molecule that can generate systemic T cell responses against the patient’s own neoantigens in situ and with a potentially benign safety profile, AGI-134 may be an ideal candidate to use in combination with the first wave of immunotherapies - the checkpoint inhibitors.
About Agalimmune
Agalimmune is a biopharmaceutical company with an innovative anti-cancer immunotherapy technology for generating a systemic, adaptive immune response to solid tumours. AGI-134, the company’s lead small molecule immunotherapeutic is in late-pre-clinical development. Agalimmune’s technology harnesses a universal & natural immune activation to drive an in-situ innate and adaptive, patient-specific anti-tumour response to the patient’s own neo-antigens. This will not only kill the tumour cells at the site of injection, but also bring about a durable anti-tumour immune response all around the body. Agalimmune's technology relies on an interaction between the alpha-Gal glycolipid Alphaject product and its interaction with anti-Gal antibodies, the most common natural antibody in humans. In each patient the anti-tumour immune response is unique to their cancer.
Agalimmune was established in 2013 and is headquartered in London, UK with laboratories in Sandwich, UK and Boston area, US.
London, UK, May 25, 2016 – Agalimmune Ltd, an innovative anti-cancer immunotherapy biopharmaceutical company developing treatments for patients with solid tumours, announces today that Dr Sascha Kristian, Research Director, Agalimmune, will deliver a presentation on Agalimmune’s lead clinical candidate, AGI-134 and its potent anti-tumour activity. The presentation will be delivered at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting, June 3-7 2016 in Chicago, Illinois, US.
AGI-134 is in development for the treatment of solid tumours and is in preparation for a phase I/II clinical study. AGI-134 is a fully synthetic, alpha-Gal glycolipid-like small molecule with a unique mechanism of action that drives a patient-specific anti-tumour response in situ.
The presentation (abstract ID 3083) is entitled “AGI-134, a fully synthetic a-Gal-based cancer immunotherapy that shows synergy with an anti-PD-1 antibody and favourable pre-clinical pharmacokinetic and toxicity profiles”. It will provide the latest results demonstrating that AGI-134 displays potent anti-tumour activity. AGI-134 engages the cellular and humoral immune systems in situ against autologous tumour neoantigens, to attack the patient’s own tumour cells all around the body.
The presentation includes data generated in an in-vivo model of melanoma. These data show that AGI-134 monotherapy induces an immune response that prevents the growth of distant untreated lesions. Importantly they also show that AGI-134 combines synergistically with an anti-PD1 checkpoint inhibitor. In addition, the results show that AGI-134 has an ideal profile as a clinical candidate with very good tolerability and favourable pharmacokinetics.
The presentation will be made in the poster session Developmental Therapeutics—Immunotherapy on Sunday 5 June between 8.00am and 11.30am.
“This presentation highlights the strong potential of AGI-134 as a novel immunotherapy for solid tumours. The unique mechanism of action of AGI-134 addresses directly two key issues in cancer therapy. The first is inter and intra-patient tumour neoantigen heterogeneity. This has recently been highlighted in a key paper in Science [1]. The second is the non-inflammatory, or cold, tumour microenvironment, that limits responsiveness to existing immunotherapies,” said Dr. Sascha Kristian, Research Director at Agalimmune. “Current immunotherapies alone lead to durable responses in less than half of patients and are associated with significant side effects. There is a huge need for therapies like AGI-134 that can increase the frequency and duration of responses. Furthermore, as a small molecule that can generate systemic T cell responses against the patient’s own neoantigens in situ and with a potentially benign safety profile, AGI-134 may be an ideal candidate to use in combination with the first wave of immunotherapies - the checkpoint inhibitors.
About Agalimmune
Agalimmune is a biopharmaceutical company with an innovative anti-cancer immunotherapy technology for generating a systemic, adaptive immune response to solid tumours. AGI-134, the company’s lead small molecule immunotherapeutic is in late-pre-clinical development. Agalimmune’s technology harnesses a universal & natural immune activation to drive an in-situ innate and adaptive, patient-specific anti-tumour response to the patient’s own neo-antigens. This will not only kill the tumour cells at the site of injection, but also bring about a durable anti-tumour immune response all around the body. Agalimmune's technology relies on an interaction between the alpha-Gal glycolipid Alphaject product and its interaction with anti-Gal antibodies, the most common natural antibody in humans. In each patient the anti-tumour immune response is unique to their cancer.
Agalimmune was established in 2013 and is headquartered in London, UK with laboratories in Sandwich, UK and Boston area, US.
